Department of Cardiovascular Medicine, National Cardiovascular Center, Suita 565-8565, Japan.
Cardiovasc Res. 2010 Jan 15;85(2):339-46. doi: 10.1093/cvr/cvp282. Epub 2009 Aug 14.
The cardiac proteasome is a complex, heterogeneous, and dynamic organelle. Its function is regulated by its molecular organization, post-translational modifications, and associated partner proteins. Pressure overload, ischaemic heart disease, or genetic mutations in contractile proteins can cause heart failure, during which misfolded protein levels are elevated. At the same time, numerous interconnected signal transduction pathways are activated that may modulate any of the three proteasomal regulatory mechanisms mentioned above, resulting in functional changes in cardiac proteasomes. Many lines of evidence support the important role of the ubiquitin-proteasome system (UPS) in the development of heart diseases. Many researchers have focused on the UPS, applying new drug discovery methods not only in the field of cancer research but also in cardiovascular fields such as cardiac hypertrophy and ischaemic heart diseases. More understanding of UPS in the pathophysiology of heart diseases will lead to new routes for therapy.
心脏蛋白酶体是一种复杂、异质和动态的细胞器。其功能受其分子组成、翻译后修饰和相关伴侣蛋白的调节。压力超负荷、缺血性心脏病或收缩蛋白的基因突变可导致心力衰竭,在此期间,错误折叠的蛋白质水平升高。同时,许多相互关联的信号转导途径被激活,这些途径可能调节上述三种蛋白酶体调节机制中的任何一种,从而导致心脏蛋白酶体的功能变化。大量证据支持泛素-蛋白酶体系统(UPS)在心脏疾病发展中的重要作用。许多研究人员专注于 UPS,不仅在癌症研究领域,而且在心血管领域,如心脏肥大和缺血性心脏病,应用新的药物发现方法。对 UPS 在心脏疾病病理生理学中的更多了解将为治疗开辟新途径。